Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies

19Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

More than 2000 immuno-oncology agents are being tested or are in use as a result of the cancer immunotherapy revolution. Manipulation of co-inhibitory receptors has achieved tumor eradication in a minority of patients, but widespread immune-related adverse events (irAEs) compromised tolerance to healthy self-tissues in the majority. We have proposed that a major mechanism of irAEs is similar to a graft-versus-malignancy effect of graft-versus-host disease. To verify our hypothesis, we retrieved post-marketing data of adverse events from the U.S. Food and Drug Administration Adverse Event Reporting System. A significant positive correlation was revealed in 7677 patients between the reporting odds ratio of irAEs during immune checkpoint inhibitor therapy and the corresponding tumor mutational burden across 19 cancer types. These results can be interpreted to mean that the ICI drugs unleashed T cells against “altered-self,” self, and tumors resulting in better overall survival.

References Powered by Scopus

Signatures of mutational processes in human cancer

7374Citations
N/AReaders
Get full text

Genetic basis for clinical response to CTLA-4 blockade in melanoma

3460Citations
N/AReaders
Get full text

Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline

2722Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends

135Citations
N/AReaders
Get full text

Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution

26Citations
N/AReaders
Get full text

Clinical and translational attributes of immune-related adverse events

19Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kerepesi, C., Bakacs, T., Moss, R. W., Slavin, S., & Anderson, C. C. (2020, May 1). Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies. Cancer Immunology, Immunotherapy. Springer. https://doi.org/10.1007/s00262-020-02543-6

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

60%

Researcher 3

20%

Professor / Associate Prof. 2

13%

Lecturer / Post doc 1

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

54%

Pharmacology, Toxicology and Pharmaceut... 2

15%

Nursing and Health Professions 2

15%

Biochemistry, Genetics and Molecular Bi... 2

15%

Save time finding and organizing research with Mendeley

Sign up for free